Visiongain reports

How will the in vitro diagnostics (IVD) market develop this decade? Our report shows you potential revenues to 2021, discussing opportunities and prospects. Through our research and analysis we aim to save you time and help in your decisions.

GPCR & Kinase Targets Advances in drug discovery from molecular to clinical 14th - 15th April 2011, Thistle City Barbican, London, UK

Dermatological drugs form an important segment of the global pharma market, with sales of over $25bn in 2009. New drugs with improved safety and efficacy can gain significant market shares in the future, our study reveals.

All sectors of the market have been expanding, but which will fare best from 2010 onwards? How will those submarkets, and the overall market sector, cope with patent expiries this decade? How will leading national markets perform from 2010 to 2026?

Our new report shows you trends to watch. Novel and generic drug producers can benefit from emerging and established drug delivery technologies.

Vaccine shortage during recent outbreaks,such as avian flu & swine flu,highlighted the shortcoming of some production method & operation. Newer manufacturing systems are being developed, with manufacturer influenced by demand-side & regulatory needs.

Our new report examines the antithrombotic and anticoagulant sector critically. We harness primary and secondary research to meet your needs. We provide revenue forecasts, market share analyses, pipeline developments and other data.

Our report will give you present & future revenue values for the generics sector, globally & nationally. You can assess the strengths, weaknesses and revenue trends for generic drugs from 2010 to 2025. We aim to save you time and benefit your work.

Our new report examines the pharma regulatory landscape critically. We harness primary and secondary research to meet your needs. This report provides analyses of global trends, including cost forecasts.

Contract manufacturing services in emerging countries are increasingly prominent. That trend is accelerated by rising numbers of contract manufacturing organisations (CMOs) in those countries and the globalisation of pharma manufacturing.